Kalyan Roy: Polycythaemia Rubra Vera – More Than Just Elevated Hemoglobin
Kalyan Roy, Transfusion Medicine Specialist at Square Hospitals LTD, shared a post on LinkedIn:
“Polycythaemia Rubra Vera (PV): More Than Just Elevated Hemoglobin
Polycythaemia Vera (PV) is a chronic JAK2 mutation–driven myeloproliferative neoplasm characterized by uncontrolled red blood cell production, often accompanied by leukocytosis and thrombocytosis. The resulting hyperviscosity syndrome significantly increases the risk of arterial and venous thrombosis, making early diagnosis and appropriate management essential.
Key Clinical Highlights
- JAK2 V617F mutation present in ~95–98% of cases
- Elevated hemoglobin, hematocrit, and red cell mass
- Common symptoms: headache, dizziness, visual disturbances, aquagenic pruritus, and erythromelalgi
- Increased risk of stroke, myocardial infarction, DVT, pulmonary embolism, and splanchnic vein thrombosi
- Low serum erythropoietin (EPO) is a characteristic laboratory finding
WHO Diagnostic Corner
Elevated Hb/Hct
Hypercellular bone marrow with trilineage proliferation
Presence of JAK2 mutation
Low serum EPO supports the diagnosis
Transfusion Medicine Perspective
Therapeutic Phlebotomy remains the cornerstone of treatment and the most important intervention performed by Transfusion Medicine services.
Treatment Goals:
- Maintain hematocrit <45%
- Reduce blood viscosity
- Prevent thrombotic complications
- Control symptoms and disease progression
Take-Home Message
Early recognition and optimal hematocrit control significantly reduce morbidity and mortality in PV. Therapeutic phlebotomy, antiplatelet therapy, and risk-adapted cytoreductive treatment remain the foundation of modern management.”

Find more posts featuring Kalyan Roy on Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C